Pregabalin for the treatment of fibromyalgia

Smith, Maree T. and Moore, Brendan J. (2012) Pregabalin for the treatment of fibromyalgia. Expert Opinion on Pharmacotherapy, 13 10: 1527-1533. doi:10.1517/14656566.2012.687373

Author Smith, Maree T.
Moore, Brendan J.
Title Pregabalin for the treatment of fibromyalgia
Journal name Expert Opinion on Pharmacotherapy   Check publisher's open access policy
ISSN 1465-6566
Publication date 2012-07-01
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1517/14656566.2012.687373
Volume 13
Issue 10
Start page 1527
End page 1533
Total pages 7
Language eng
Formatted abstract
Introduction: Fibromyalgia (FM) is the most common cause of chronic widespread body pain in humans. Co-morbidities include sleep disturbance, fatigue, impaired physical functioning, altered mood and negative effects on health-related quality of life. Pregabalin inhibits presynaptic release of pronociceptive neurotransmitters in the CNS; this likely underpins its therapeutic benefit in patients with FM.
Areas covered: This review addresses pregabalin pharmacokinetics, efficacy and adverse event (AE) profiles from randomized controlled trials and open-label extension studies in patients with FM. These effects are compared with those of the serotonin norepinephrine reuptake inhibitors, duloxetine and milnacipran that also have FDA approval for the treatment of fibromyalgia.
Expert opinion: At the approved dosages, oral pregabalin has at most a moderate therapeutic benefit above placebo with tolerable side-effects, in no more than 50% of patients with FM. Durability of clinically meaningful (≥ 30%) pain relief in pregabalin-responders has been demonstrated for at least 6-months, but longer-term studies are required as most patients have symptoms for decades. Exclusion of patients with common co-morbidities from the pregabalin RCTs in FM raises questions on the generalizability of the RCT findings to the typical patient seen in clinical practice and so additional investigation is required.
Keyword Adverse events
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Official 2013 Collection
School of Pharmacy Publications
Centre for Integrated Preclinical Drug Development Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 12 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 12 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 24 Jun 2012, 22:04:46 EST by Professor Maree Smith on behalf of School of Pharmacy